Only specific tests can uncover
TRK fusion cancer

  • While NTRK gene fusions were one of the first oncogenes identified, they are not routinely tested for and/or included on all test platforms1,2
  • TRK fusion cancers can be detected through a number of testing methodologies; however, only sensitive and specific tests can reliably detect NTRK gene fusions1,2
Next-generation Sequencing
Next-generation sequencing (NGS) provides the most comprehensive view of a large number of genes and may identify NTRK gene fusions as well as other actionable alterations.3,4 However, it is important to know whether the NGS assay used has the capacity to detect NTRK gene fusions.3,5
Immunohistochemistry
Immunohistochemistry (IHC) Pan-TRK IHC antibodies detect TRK proteins A,B,C, which may be expressed in both wild-type and fusion proteins. Protein expression may not be the result of a gene fusion event.6
DNA fluorescence in situ hybridization
DNA fluorescence in situ hybridization (FISH) testing may have limited utility in uncovering NTRK gene fusions because it is not designed for multiplexing. In order to detect fusions at multiple locations, such as the 3 NTRK genes, multiple FISH tests would need to be run. Additionally, it can require a highly specialized pathology analysis.3,5,8
Reverse transcription polymerase chain reaction
Reverse transcription polymerase chain reaction (RT-PCR) is designed to identify only known translocation partners and breakpoints and cannot identify novel breakpoints or novel fusion partners.9
Collaboration between oncologists and pathology lab partners can help determine which tests are appropriate to detect TRK fusion cancer.

REGISTER

Sign up to receive additional information.
Kindly enter valid email address
Register

References: 1. Vaishnavi A, Le AT, Doebele RC. Cancer Discov. 2015;5(1):25-34. 2. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129. doi:10.1186/s13073-015-0252-1. 3. Abel HJ, Al-Kateb H, Cottrell CE, et al. Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn. 2014;16(4):405-417. 4. Rogers T-M, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259. doi:10.1038/srep42259. 5. Abel HJ, Duncavage EJ. Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches. Cancer Genet. 2013;206(12):432-440. 6. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551. 7. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PHB. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937-946. 8. Amatu A, Sartore-Bianchi, Siena S. ESMO Open. 2016;1(2):e000023. 9. Abel H, Pfeifer J, Duncavage E. Translocation detection using next-generation sequencing. In: Kulkarni S, Pfeifer J, eds. Clinical Genomics. Amsterdam, Netherlands: Elsevier/Academic Press; 2015:151-164.